Update on anti-CTLA-4 antibodies in clinical trials

• PEGGS KS, QUEZADA SA, KORMAN AJ, ALLISON JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. (2006) 18(2):206-213.
   PubMed Web of Science ®Google Scholar
• DAVIS SJ, IKEMIZU S, EVANS EJ et al.: The nature of molecular recognition by T cells. Nat. Immunol. (2003) 4(3):217-224.
   PubMed Web of Science ®Google Scholar
• SALOMON B, BLUESTONE JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann. Rev. Immunol. (2001) 19:225-252.
   PubMed Web of Science ®Google Scholar
• PEREZ VL, VAN PARIJS L, BIUCKIANS A et al.: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6(4):411-417.
   PubMed Web of Science ®Google Scholar
• WATERHOUSE P, PENNINGER JM, TIMMS E et al.: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 270(5238):985-988.
   PubMed Web of Science ®Google Scholar
• TIVOL EA, BORRIELLO F, SCHWEITZER AN et al.: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3(5):541-547.
   PubMed Web of Science ®Google Scholar
• CHAMBERS CA, SULLIVAN TJ, ALLISON JP: Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 7(6):885-895.
   PubMed Web of Science ®Google Scholar
• WALKER LS, AUSUBEL LJ, CHODOS A, BEKARIAN N, ABBAS AK: CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen. J. Immunol. (2002) 169(11):6202-6209.
   PubMed Web of Science ®Google Scholar
• SANTULLI-MAROTTO S, NAIR SK, RUSCONI C, SULLENGER B, GILBOA E: Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. (2003) 63(21):7483-7489.
   PubMed Web of Science ®Google Scholar
• HURWITZ AA, FOSTER BA, KWON ED et al.: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. (2000) 60(9):2444-2448.
   PubMed Web of Science ®Google Scholar
• ESPENSCHIED J, LAMONT J, LONGMATE J et al.: CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J. Immunol. (2003) 170(6):3401-3407.
   PubMed Web of Science ®Google Scholar
• VAN ELSAS A, HURWITZ AA, ALLISON JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. (1999) 190(3):355-366.
   PubMed Web of Science ®Google Scholar
• HURWITZ AA, YU TF, LEACH DR, ALLISON JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA (1998) 95(17):10067-10071.
   PubMed Web of Science ®Google Scholar
• LEACH DR, KRUMMEL MF, ALLISON JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271(5256):1734-1736.
   PubMed Web of Science ®Google Scholar
• VAN ELSAS A, SUTMULLER RP, HURWITZ AA et al.: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. (2001) 194(4):481-489.
   PubMed Web of Science ®Google Scholar
• KWON ED, FOSTER BA, HURWITZ AA et al.: Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. USA (1999) 96(26):15074-15079.
   PubMed Web of Science ®Google Scholar
• KWON ED, HURWITZ AA, FOSTER BA et al.: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA (1997) 94(15):8099-8103.
   PubMed Web of Science ®Google Scholar
• KELER T, HALK E, VITALE L et al.: Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. (2003)171(11):6251-6259.
   PubMed Web of Science ®Google Scholar
• HANSON DC, CANNIFF PC, PRIMIANO MJ et al.: Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proceedings of the American Association for Cancer Research. Orlando, FL, USA (2004).
   Google Scholar
• SALGALLER M: IDDB Meeting Report. Cancer Vaccines and Immunotherapy – Fifth Annual Colloquium, (Part 1), Models for Cancer Vaccines. Walker's Cay, Bahamas (2003).
   Google Scholar
• MILLHAM R, PAVLOV D, CANNIFF P et al.: Ex vivo blood stimulation assay as a translational research tool in the development of the CP-675, 206 (CP-675, 206). American Society of Clinical Oncology, Annual Meeting Proceedings (Part I). Atlanta, GA, USA (2006).
   Google Scholar
• PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100(14):8372-8377.
   PubMed Web of Science ®Google Scholar
• JERMUTUS L: Phage Display Technologies – SMi Conference. London, UK (2002).
   Google Scholar
• SMALL EJ, TCHEKMEDYIAN NS, RINI BI et al.: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. (2007) 13(6):1810-1815.
   PubMed Web of Science ®Google Scholar
• TCHEKMED YIAN S, GLASBY J, KORMAN A et al.: MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma. Proceedings of the American Society of Clinical Oncology. Orlando, FL, USA (2002).
   Google Scholar
• SANDERSON K, SCOTLAND R, LEE P et al.: Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected Stages III and IV melanoma. J. Clin. Oncol. (2005) 23(4):741-750.
   PubMed Web of Science ®Google Scholar
• RIBAS A, CAMACHO LH, LOPEZ-BERESTEIN G et al.: Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. (2005) 23(35):8968-8977.
   PubMed Web of Science ®Google Scholar
• CAMACHO LH, RIBAS A, GLASPY JA et al.: Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. American Society of Clinical Oncology, Annual Meeting. New Orleans, LA, USA (2004).
   Google Scholar
• RIBAS A, BOZON VA, LOPEZ-BERESTEIN G et al.: Phase 1 Trial of Monthly Doses of the Human Anti-CTLA4 Monoclonal Antibody CP-675,206 in Patients with Advanced Melanoma. American Society of Clinical Oncology, Annual Meeting. Orlando, FL, USA (2005).
   Google Scholar
• MORSE MA: Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr. Opin. Mol. Ther. (2005) 7(6):588-597.
   PubMed Web of Science ®Google Scholar
• JANIK JE, MORRIS JC, QUINN C et al.: A pilot study of MDX-010 after vaccine failure in patients with advanced malignancy. Blood (2003) 102(11).
   Google Scholar
• GERRITSEN W, VAN DEN EERTWEGH AJ, DE GRUIJL TD et al.: A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipiluminab) in patients with metastatic hormone-refractory prostate cancer (MHRPC). American Society for Clinical Oncology Prostate Cancer Symposium. Orlando, FL, USA (2007).
   Google Scholar
• YANG JC, CHILDS R: Immunotherapy for renal cell cancer.J. Clin. Oncol. (2006) 24(35):5576-5583.
   PubMed Web of Science ®Google Scholar
• BECK KE, BLANSFIELD JA, TRAN KQ et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. (2006) 24(15):2283-2289.
   PubMed Web of Science ®Google Scholar
• YANG JC, BECK KE, BLANSFIELD JA et al.: Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). American Society of Clinical Oncology, Annual Meeting. Orlando, FL, USA (2005).
   Google Scholar
• FISCHKOFF SA, HERSH E, WEBER J et al.: Durable responses and long-term progression-free survival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. American Society for Clinical Oncology, Annual Meeting. Orlando, FL, USA (2005).
   Google Scholar
• SMALL E, HIGANO C, TCHEKMEDYIAN N et al.: Randomized Phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. American Society for Clinical Ocology, Annual Meeting. Atlanta, GA, USA (2006).
   Google Scholar
• ATTIA P, GIAO PQ, MICHAEL YJ, SA R: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4. Proceedings of the American Association for Cancer Research. Anaheim, CA, USA (2005).
   Google Scholar
• ATTIA P, PHAN GQ, MAKER AV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. (2005) 23(25):6043-6053.
   PubMed Web of Science ®Google Scholar
• WEBER JS, TARGAN S, SCOTLAND R et al.: Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected Stages IIIC and IV melanoma. American Society of Clinical Oncology, Annual Meeting. Atlanta, GA, USA (2006).
   Google Scholar
• MAKER AV, PHAN GQ, ATTIA P et al.: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. (2005) 12(12):1005-1016.
   PubMed Web of Science ®Google Scholar
• GOMEZ-NAVARRO J, ANTONIA S, SOSMAN J et al.: Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a Phase I/II study. American Society of Clinical Oncology. Orlando, FL, USA (2007) (Abstract 8524).
   Google Scholar
• RIBAS A, COMIN-ANDUIX B, BOZON V et al.: Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb CP-675, 206. American Society of Clinical Oncology, Annual Meeting. Atlanta, GA, USA (2006).
   Google Scholar
• REUBEN JM, LEE BN, SHEN DY et al.: Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM). American Society for Clinical Oncology Annual Meeting. Orlando. FL, USA (2005).
   Google Scholar
• REUBEN JM, LEE BN, LI C et al.: Biologic and immunomodulatory events after CTLA-4 blockade with CP-675,206 in patients with advanced malignant melanoma. Cancer (2006) 106(11):2437-2444.
   PubMed Web of Science ®Google Scholar
• CHUNG KY, GORE I, FONG L et al.: A Phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum. ASCO Annual Meeting Proceedings (Part I). (2007) 25(18S)(20 Suppl.):3035.
   Google Scholar
• EVANS L: IDDB Meeting Report. American Society of Clinical Oncology, Annual Meeting. Orlando, FL, USA (2002).
   Google Scholar
• SALGALLER M: IDDB Meeting Report. Cancer Vaccines 2003 – Knowledge Foundation Second International Conference on Advances in Designing Cancer Vaccines. Boston, MA, USA (2003).
   Google Scholar
• HERSH EM, WEBER J, POWDERLY J et al.: A Phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in Stage IV metastatic malignant melanoma. American Society of Clinical Oncology, Annual Meeting. New Orleans, LA, USA (2004).
   Google Scholar
• MCGAHA T, MURPHY JW: CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect. Immunol. (2000) 68(8):4624-4630.
   PubMed Web of Science ®Google Scholar
• GOMES NA, BARRETO-DE-SOUZA V, WILSON ME, DOSREIS GA: Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 molecular pathway. J. Infect. Dis. (1998) 178(6):1847-1851.
   PubMed Web of Science ®Google Scholar
• RILEY JL, SCHLIENGER K, BLAIR PJ et al.: Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J. Exp. Med. (2000) 191(11):1987-1997.
   PubMed Web of Science ®Google Scholar

Patents

• MEDAREX: WO00114424 (2001).
   Google Scholar

Websites

• http://www.amgen.com/pdfs/abgenix/2001-12-04.pdf Abgenix Introduces Enhanced Version of XenoMouse Technology (2001).
   Google Scholar
• http://www.medarex.com/cgi-local/item.pl/20070222-966145 Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase I Combination Therapy Trial with GVAX(TM) Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody (2007).
   Google Scholar
• http://www.medarex.com/cgi-local/item.pl/20061211-941138Ipilimumab (MDX-010) Safety and Clinical Response Data in Lymphomas and Leukemia Presented at the 48th American Society of Hematology Annual Meeting (2006).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00083278;jsessionid=776B58F8AEAC535ED62FDA518495D72E?order=3 Study of MDX-010 in Stage IV Breast Cancer (2007).
   Google Scholar
• http://www.medarex.com/cgi-local/item.pl/20050307-682075 Medarex and Bristol-Myers Squibb Announce Complete and Partial Responses Observed in Phase I/II Clinical Study of MDX-010 in Combination with IL-2 (2005).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00162123?order=1 A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00094653?order=1 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients with Melanoma (2006).
   Google Scholar
• http://www.medarex.com/cgi-local/item.pl/20040928-619932 Medarex Commences Enrollment in Phase III Clinical Trial for MDX-010 in Metastatic Melanoma (2004).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00324155;jsessionid=3AB353A3AEA9BD590982EE930CF71860?order=11 Dacarbazine and Ipilimumab vs. Dacarbazine with Placebo in Untreated Unresectable Stage III or IV Melanoma (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/gui/show/NCT00090896;jsessionid=1CFA7768D947F0F3FB42B2AFAF97505E?order=25CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined with Dendritic Cell Vaccine Therapy in Treating Patients with Stage III or Stage IV Melanoma that cannot be Removed with Surgery (2007).
   Google Scholar
• http://www.rxlist.com/cgi/generic/sutent_cp.htm Sutent Clinical Pharmacology (2007).
   Google Scholar
• http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=306520SU011248 (2005).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00372853;jsessionid=A860789413E29D1432F8C1A428A7FEBF?order=31 Dose-Finding Study of CP-675,206 and SU011248 in Patients with Metastatic Renal Cell Carcinoma not Previously Treated (2007).
   Google Scholar
• http://clinicaltrial.gov/ct/gui/show/NCT00431275;jsessionid=FCE71900BAD5B2343D8285B1583EF026?order=14 Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00075192?order=1 CP-675,206 with Neoadjuvant Hormone Therapy in Patients with High Risk Prostate Cancer (2006).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00086489CP-675,206 in Patients with Advanced Melanoma (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00254579?order=10 Phase II Study of CP-675,206 in Refractory Melanoma (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00312975;jsessionid=4205C01407598BB1838B9AB6A7126102?order=3 Phase II Randomized Study of CP-675,206 or Best Supportive Care Immediately after Platinum-Based Therapy for NSCLC (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00257205?order=11 Phase III Trial of CP-675,206 Versus Either Dacarbazine or Temozolomide in Patients without Prior Therapy (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00057889?order=1 Monoclonal Antibody Therapy in Treating Patients with Metastatic Renal Cell Cancer (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00047164?order=1 Monoclonal Antibody Therapy in Treating Patients with Lymphoma or Colon Cancer that has not Responded to Vaccine Therapy (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00170157?order=1 MDX-010 for Advanced Prostate Cancer (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00135408?order=1 A Study of MDX-010 (BMS-734016) Administered with or without Prophylactic Oral Budesonide (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00289627?order=1 A Single Arm Study of Ipilimumab Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00357461?order=1 Ipilimumab with or without Vaccine Therapy in Treating Patients with Previously Treated Stage IV Melanoma (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00112580?order=1 MDX-010 in Treating Patients with Stage IV Pancreatic Cancer that cannot be Removed by Surgery (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00289640?order=1 Study of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00028431?order=1 Novel Adjuvants for Peptide-Based Melanoma Vaccines (2005).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00261365?order=1 Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00323882?order=1 Study of MDX-010 in Patients with Metastatic Hormone-Refractory Prostate Cancer (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00089076?order=1 MDX-010 in Treating Patients with Recurrent or Refractory Lymphoma (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00039091?order=1 Monoclonal Antibody Therapy in Treating Patients with Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00064129?order=1 Monoclonal Antibody and Sargramostim in Treating Patients with Metastatic Prostate Cancer (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00060372?order=1 Monoclonal Antibody Therapy after Allogeneic Stem Cell Transplantation in Treating Patients with Persistent or Progressive Cancer (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00124670?order=1 Vaccine Therapy, MDX-010, and GM-CSF in Treating Patients with Metastatic Prostate Cancer (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00362713?order=1 Study of Neoadjuvant Ipilimumab in Patients with Urothelial Carcinoma Undergoing Surgical Resection (2007).
   Google Scholar
• http://clinicaltrials.gov/ct/show/NCT00378482?order=4 A Rollover Protocol for Patients Who Received CP-675,206 in other Protocols (2007).
   Google Scholar